Loading…
Inovio Pharmaceuticals, Inc. is projected to rise to $0.7646 by 2027, a +13% move from its current price of $0.6968. INO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6661 | $0.6961 | $0.7275 | -0.10% |
| Aug 6 | $0.6534 | $0.6954 | $0.7402 | -0.20% |
| Aug 7 | $0.6436 | $0.6947 | $0.7499 | -0.30% |
| Aug 8 | $0.6354 | $0.694 | $0.758 | -0.40% |
| Aug 9 | $0.6282 | $0.6933 | $0.7652 | -0.50% |
| Aug 10 | $0.6217 | $0.6927 | $0.7717 | -0.59% |
| Aug 11 | $0.6158 | $0.692 | $0.7776 | -0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6158 | $0.692 | $0.7776 | -0.69% |
| Week 2 | $0.5826 | $0.6872 | $0.8105 | -1.38% |
| Week 3 | $0.5575 | $0.6824 | $0.8353 | -2.06% |
| Week 4 | $0.5366 | $0.6777 | $0.8558 | -2.74% |
| Week 5 | $0.5184 | $0.673 | $0.8736 | -3.42% |
| Week 6 | $0.5022 | $0.6683 | $0.8895 | -4.09% |
| Week 7 | $0.4874 | $0.6637 | $0.9038 | -4.75% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Inovio Pharmaceuticals, Inc. is a biotechnology company focusing on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses SynCon to engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices that facilitate delivery of the DNA plasmids.
Its lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its pipeline includes VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
INO is trading at $0.656 with a market cap of $53.97M and holds a rank of 4252.
The 30-day price range is $0.4877 to $0.8823, framing a volatile near-term environment.
Technical picture shows RSI14 at 20, with SMA50 at $1.14 and SMA200 at $1.59. Near-term support sits at $0.66 and resistance at $1.22.
Forecasts outline a multi-year uptrend, starting with 2026 avg $0.656 (ROI 0) and 2027 avg $0.7372 (ROI 12.4), advancing to 2028 avg $0.8236 (ROI 25.5), 2029 avg $0.9085 (ROI 38.5), 2030 avg $1.03 (ROI 56.7), 2040 avg $1.30 (ROI 97.5), and 2050 avg $2.83 (ROI 332), with sentiment moving from NEUTRAL in early years to BULLISH in later years.
A major floor 57.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.3% below — buyers have tended to step in here.
The nearest ceiling, 75.1% above — a clean break opens room to run.
A major ceiling 149.7% above — clearing it would confirm fresh momentum.
Key INO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of INO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.876 | Sell | $0.8297 | Sell |
| MA 10 | $0.962 | Sell | $0.9253 | Sell |
| MA 20 | $1.06 | Sell | $1.01 | Sell |
| MA 50 | $1.13 | Sell | $1.11 | Sell |
| MA 100 | $1.24 | Sell | $1.25 | Sell |
| MA 200 | $1.58 | Sell | $1.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 22.05 | Buy |
| Stoch RSI (14) | 7.45 | Buy |
| CCI (20) | -235.47 | Sell |
| Williams %R (14) | -96.08 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -41.88 | Sell |
| Bollinger %B (20,2) | -0.14 | Buy |
| Stochastic %K (14) | 3.92 | Buy |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -0.21 | Sell |
| Ultimate (7,14,28) | 18.05 | Buy |
| Momentum (10) | -0.44 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 0.78 | Sell |
| ADX (14) | 24.08 | Sell |
| ATR (14) | 0.05 | Info |
Near term, the RSI of 20 suggests the stock is in an oversold region, aligning with a low current price near support.
The 30-day range runs from $0.4877 to $0.8823, while key levels include support at $0.66 and resistance at $1.22. The SMA50 at $1.14 and the SMA200 at $1.59 provide context for potential mechanics of a bounce or pullback in the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.66 | $0.677 | $0.788 | 0% | Neutral | |
| $0.5758 | $0.7646 | $1.09 | +13% | Neutral | |
| $0.6158 | $0.8586 | $1.30 | +27% | Bullish | |
| $0.6469 | $0.9398 | $1.48 | +39% | Bullish | |
| $0.7064 | $1.06 | $1.74 | +57% | Bullish | |
| $0.6203 | $0.9673 | $1.63 | +43% | Bullish | |
| $0.6026 | $0.9705 | $1.68 | +43% | Bullish | |
| $0.5899 | $0.9796 | $1.74 | +45% | Bullish | |
| $0.5294 | $0.9054 | $1.64 | +34% | Bullish | |
| $0.7213 | $1.27 | $2.35 | +88% | Bullish | |
| $0.6811 | $1.37 | $2.76 | +103% | Bullish | |
| $1.33 | $2.96 | $6.72 | +337% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.66 | $0.677 | $0.7847 | -2.84% |
| September 2026 | $0.5403 | $0.6506 | $0.8133 | -3.90% |
| October 2026 | $0.5227 | $0.6365 | $0.8092 | -2.17% |
| November 2026 | $0.4827 | $0.5933 | $0.7645 | -6.79% |
| December 2026 | $0.4874 | $0.6041 | $0.788 | +1.83% |
Click any year to see its month-by-month INO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The INO price prediction for 2026 points to an average of $0.677 (low $0.66, high $0.788) — a potential gain of 0% on today's $0.6968. A consolidation phase looks the most probable path here.
In 2027, INO is projected to trade between $0.5758 and $1.09, averaging $0.7646 — a potential gain of +13% from today's $0.6968. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
Inovio Pharmaceuticals, Inc.'s 2028 outlook centres on $0.8586, within a $0.6158 to $1.30 range. That is up +12% on the projected 2027 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, INO could reach as high as $1.48, with a base case around $0.9398 and support toward $0.6469 — roughly +39% from $0.6968. Momentum favours further upside here.
Expect INO to range from $0.7064 to $1.74 through 2030. The $1.06 average target implies a +57% move from current prices. That is up +13% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The INO price prediction for 2031 points to an average of $0.9673 (low $0.6203, high $1.63) — a potential gain of +43% on today's $0.6968. Momentum favours further upside here.
In 2032, INO is projected to trade between $0.6026 and $1.68, averaging $0.9705 — a potential gain of +43% from today's $0.6968. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Inovio Pharmaceuticals, Inc.'s 2033 outlook centres on $0.9796, within a $0.5899 to $1.74 range. That is up +1% on the projected 2032 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2034, INO could reach as high as $1.64, with a base case around $0.9054 and support toward $0.5294 — roughly +34% from $0.6968. Buyers look set to stay in control over this stretch.
Expect INO to range from $0.7213 to $2.35 through 2035. The $1.27 average target implies a +88% move from current prices. That is up +40% on the projected 2034 average. Momentum favours further upside here.
The INO price prediction for 2040 points to an average of $1.37 (low $0.6811, high $2.76) — a potential gain of +103% on today's $0.6968. Buyers look set to stay in control over this stretch.
In 2050, INO is projected to trade between $1.33 and $6.72, averaging $2.96 — a potential gain of +337% from today's $0.6968. That is up +116% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in INO today (≈ 1,435.132032 INO) could be worth
$4,248.15
+$3,248.15 (+325%) by 2050 · US Dollar
Based on the average projected INO price of $2.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in INOwould be worth at today's price.
$1,000 invested in INO on Jul 31, 2025 (≈ 704.225373 INO) would be worth
$490.7
-$509.3 (-50.9%) today · 0.49× · US Dollar
Based on a INO entry price of $1.42 vs. today's $0.6968.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.97 | $718.35 | -28.2% |
| 1 month ago | $1.19 | $585.55 | -41.4% |
| 3 months ago | $1.1 | $633.45 | -36.7% |
| 6 months ago | $1.7 | $409.88 | -59.0% |
| 1 year ago | $1.42 | $490.7 | -50.9% |
| All time (5.0y) ago | $110.88 | $6.28 | -99.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our INO forecast.
Our base-case forecast reaches $1.40 around 2050.
Implied market cap at $1.40: $115.18M
Looking further out, the forecast paints a bullish multi-year trajectory. In 2030 the average price is projected at $1.03 with a 56.7 ROI, rising to $1.30 on average by 2040 (ROI 97.5) and $2.83 on average by 2050 (ROI 332). Other mid-range years show gradual gains, with 2027 average $0.7372 (ROI 12.4) and 2028 average $0.8236 (ROI 25.5).
The sentiment outlook shifts from NEUTRAL in 2026 and 2027 to BULLISH from 2028 onward.
These figures are estimates and not guarantees. The forecasted path reflects relative price trajectories and is subject to market and company-specific risk factors, including volatility indicated by an annualized volatility of 90% in the data. The current price and near-term indicators (RSI, SMA, and support/resistance) remain important for assessing timing and risk.
Tap a question to reveal the answer.
In 2030, the forecasted avg price is $1.03, with a min of $0.6777 and a max of $1.69, and an ROI of 56.7. These figures are projections and not guarantees.
The long-term forecast shows bullish potential, with 2030 avg $1.03, 2040 avg $1.30, and 2050 avg $2.83, corresponding to ROIs of 56.7, 97.5, and 332 respectively. However, these are estimates and carry inherent uncertainty.
Yes. The forecast shows 2030 avg $1.03 and a max of $1.69, with earlier years reaching as high as $1.44 in 2029. The path suggests it can exceed $1 on a multi-year horizon.
Current price is $0.656 and market cap is $53.97M.
The 30-day range is $0.4877 to $0.8823. Near-term support is $0.66 and resistance is $1.22.
Inovio Pharmaceuticals, Inc. Community Discussion
0Share your Inovio Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.